Examining the effects of extended-injectable buprenorphine for those using high potency synthetic opioids.
Official title: A Randomized Controlled Trial Examining Extended-Injectable Buprenorphine in those who use High Potency Synthetic Opioids
Funded at Columbia University Health Sciences · NIH-10808333 · Data updated 2026-11-12
This study is looking at whether a long-lasting injection of buprenorphine can help people with opioid use disorder who are using strong synthetic opioids, by comparing their success in staying off drugs to those taking the usual sublingual buprenorphine/naloxone treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $180,360 |
| NIH project number | 1K23DA057392-01A1 |
| Project ID | NIH-10808333 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with opioid use disorder and are using high potency synthetic opioids.
✕Less likely to help
Patients who do not use high potency synthetic opioids or are under 21 years old may not benefit from this research.
What this research studies
This research investigates how extended-release injectable buprenorphine can help individuals with opioid use disorder (OUD) who are using high potency synthetic opioids (HPSO). The study aims to compare the rates of abstinence and relapse in patients receiving this treatment versus those using standard sublingual buprenorphine/naloxone. By analyzing individual responses to treatment and potential biomarkers, the research seeks to optimize medication-assisted treatment for this vulnerable population. Participants will be monitored for their physiological dependence and withdrawal symptoms throughout the study.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients struggling with opioid use disorder related to high potency synthetic opioids.
How similar studies have gone: While there is limited research specifically on extended-injectable buprenorphine for high potency synthetic opioids, similar approaches have shown promise in improving treatment adherence for opioid use disorder.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Luba, Rachel R — Columbia University Health Sciences
- Study coordinator: Luba, Rachel R
Related research
Other NIH-funded projects on the same topics.
-
Cognitive behavioral therapy and trazodone for insomnia phenotypes with high blood pressure
A clinical study tests how CBT-I and the sleep drug trazodone work for adults with insomnia and high blood pressure, focusing on a specific sleep duration pattern.
-
Shorter antifungal treatment for kids with candidemia
A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.
-
Short Course vs Standard Course Antifungal Therapy for Pediatric Candidemia
This study tests whether a shorter 7-day total antifungal treatment after an initial 7 days of echinocandin therapy is as effective as the usual 14-day course for children with candidemia.
-
Shorter antifungal treatment for kids with candidemia
A multi-center study tests whether kids with candidemia can finish treatment earlier after an initial week of antifungal therapy than the standard two weeks total.
-
Shorter antifungal treatment for kids with candidemia
This study tests whether children with candidemia can finish treatment after 7 days of an echinocandin if they are improving, instead of completing a full 14 days.
-
Shorter antifungal course for kids with candidemia
A multi-center study tests whether 7 extra days of antifungal therapy after an initial week of treatment can be shortened safely for children with candidemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.